NT5E and melanoma: Clinical trials exploring the combination of CD73 inhibitors with aPD‐(L)1 antibodies in advanced solid malignancies are currently underway globally (NCT04148937, NCT05431270, NCT04104672).[12] However, whether the combination of CD73 inhibitors with aPD‐(L)1 can enhance immunotherapy efficacy in melanoma remains to be fully explored.